Review Article
Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer
Table 8
miRNA-mediated regulation of histone kinases.
| Kinase groups | Target gene | miRNAs | Cancer tissue or cancer cell line | Reference |
| AGC | RPS6KA4 (MSK2) | miR-517a | Bladder cancer cell lines | [159] | PRKCD | miR-181a | Cervical squamous cells | [160, 161] | PRKCD | miR-181c | Ovarian cancer tissues | [162] | PRKCD | miR-224 | Ovarian papillary serous carcinoma | [163] | PRKCB | miR-197-3p | Gastric cancer | [164] | RSK2 | miR-634 | Ovarian cancer | [165] | PRKDC | miR-488-3p | Malignant melanoma | [166] | Nonreceptor tyrosine kinase families | JAK2 | mR-543 | Hepatocellular carcinoma | [167] | JAK2 | miR-216a | Pancreatic cancer | [168, 169] | JAK2 | miR-204 | Breast cancer | [170] | JAK2 | miR-204 | Non-small lung cancer cell lines | [171] | JAK2 | miR-375 | Gastric cancer | [172, 173] | JAK2 | miR-135a | Hodgkin lymphoma | [174] | JAK2 | miR-135a | Renal cancer | [175] | JAK2 | miR-135a | Gastric carcinoma | [176] | CMGC | CDK3 | miR-873 | Breast cancer | [177] | CDK3 | miR-4469 | Primary breast tumors | [178] | MAP3K8 | miR-589-5p | Hepatocellular carcinoma | [179] | MAP3K8 | miR-144-3p | Renal cell carcinoma | [180] | MAP3K8 | miR-509-3p | Renal cell carcinoma | [181] | GSK3B | miR-769 | Melanoma | [182] | Tyrosine kinase-like (TKL) | LIMK2 | miR-135a | Bladder cancer | [183] | Other kinases family | NEK6 | miR-23 | Hepatocellular carcinoma | [184] | NEK6 | miR-26 | Marek’s disease lymphoma | [185] | NEK6 | miR-506-3p | Retinoblastoma | [186] | AURKA | miR-124-3p | Bladder cancer | [187] | AURKA | miR-124-3p | Glioblastoma | [188] | AURKA | miR-32 | Non-small-cell lung cancer | [189] | AURKA | miR-137 | Multiple myeloma | [190] | AURKA | let-7 | Hepatocellular cancer | [191] | AURKA | miR-490 | Hepatocellular carcinoma | [192] | AURKA | miR-4715-3p | Gastrointestinal cancers | [193] | BUB1 | miR-490-5p | Hepatocellular carcinoma | [194] | BUB1 | miR-145-3p | Prostate cancer | [195] | CAMK | CHEK2 (Chk2) | miR-191 | Osteosarcoma | [196] | CHEK2 (Chk2) | miR-182-5p | Breast cancer | [197] | CHEK1 (Chk1) | miR-195 | Non-small-cell lung cancer | [198] | CHEK1 (Chk1) | miR-195 | Colon cancer | [199] | CHEK1 (Chk1) | miR-497 | Hepatocellular carcinoma | [200] | CHEK1 (Chk1) | miR-145 | Bladder cancer | [201] | CHEK1 (Chk1) | miR-424 | Cervical cancer | [202] | CHEK1 (Chk1) | miR-15 | Breast cancer cells | [203] | CHEK1 (Chk1) | miR-26a | Prostate cancer | [204] | DAPK3 | miR-1307 | Ovarian cancer cell lines | [205] | AMPK | miR-451 | Colorectal cancer | [206] | AMPK | miR-25-5p | Colorectal cancer | [207] | AMPK | miR-101 | Breast cancer | [208] | AMPK | miR-34 | Prostate cancer | [209] | STE | STK4 | miR-18a | Prostate cancer | [210] | PAK2 | miR-4779 | Colon cancer | [211] | PAK2 | miR-216a-5p | Breast cancer | [212] | PAK2 | miR-137 | Melanoma | [213] | PAK2 | miR-75p | Non-small-cell lung cancer | [214] | PAK2 | miR-134 | Human ovarian cancer cells | [215] | PAK2 | miR-922 | Oral squamous cell carcinoma | [216] | PAK2 | miR-26a | Hepatocellular carcinoma | [217] |
|
|